CoMind

Pre-clinical

London, United KingdomFounded 2019comind.io

CoMind Technologies Limited is pioneering non-invasive neurotechnology to transform clinical brain monitoring. The company recently announced a significant $102.5 million funding round to advance its platform, which aims to provide clinicians with unprecedented access to multiple neurophysiological signals through a single, simple measurement. Their focus is on addressing critical unmet needs in neurological care by harnessing photonics technology to improve patient outcomes.

Founded

2019

Focus

Digital HealthNeuroscience

AI Company Overview

Technology Platform

A non-invasive, photonics-based bedside platform designed to measure a comprehensive range of neurophysiological signals from a single measurement point, providing clinicians with previously inaccessible brain data.

Funding History

Total raised: $14M

Series A$12MUndisclosedApr 15, 2022

Seed$2MUndisclosedAug 15, 2020

Opportunities

The global market for non-invasive brain monitoring is large and underserved, with significant need in neurocritical care, stroke management, and perioperative monitoring.

CoMind's platform approach could enable new clinical protocols and personalized treatment strategies, creating opportunities for market leadership in next-generation neuromonitoring.

Risk Factors

Key risks include technical challenges in reliably capturing multiple neurophysiological signals non-invasively, regulatory hurdles for medical device approval, competition from established players, and the need to demonstrate clear clinical utility and cost-effectiveness to drive adoption in healthcare systems.

Competitive Landscape

CoMind competes with established medical device companies (Medtronic, Natus) offering EEG and limited optical monitoring, as well as emerging neurotech startups. Their differentiation lies in the promise of a comprehensive, multi-parameter bedside monitor using photonics to access signals currently unavailable with non-invasive methods.